S&P 500
7,441.40
+0.13%
Dow Jones
52,091.40
-0.08%
Nasdaq 100
29,957.70
+0.30%
Russell 2000
3,004.67
+0.01%
FTSE 100
10,478.30
+0.02%
Nikkei 225
72,618.80
+2.10%
Danaher

DHR Q4 2025 Earnings

Reported Jan 27, 2026 at 5:37 PM ET · SEC Source

Q4 25 EPS

$2.23

BEAT +1.79%

Est. $2.19

Q4 25 Revenue

$6.84B

BEAT +0.42%

Est. $6.81B

vs S&P Since Q4 25

-25.3%

TRAILING MARKET

DHR -19.9% vs S&P +5.4%

Full Year 2025 Results

FY 25 EPS

$7.80

FY 25 Revenue

$24.57B

Market Reaction

Did DHR Beat Earnings? Q4 2025 Results

Danaher closed out fiscal 2025 on firm footing, posting fourth-quarter revenue of $6.84 billion, up 4.6% year-over-year and modestly ahead of the $6.81 billion Wall Street had penciled in, while adjusted diluted EPS of $2.23 edged past the $2.19 cons… Read more Danaher closed out fiscal 2025 on firm footing, posting fourth-quarter revenue of $6.84 billion, up 4.6% year-over-year and modestly ahead of the $6.81 billion Wall Street had penciled in, while adjusted diluted EPS of $2.23 edged past the $2.19 consensus by 1.79%. The standout driver was the Biotechnology segment, which delivered 9.0% total sales growth and 6.0% core growth in the quarter, fueled by sustained momentum in the bioprocessing business, a result CEO Rainer Blair credited to "better-than-expected performance across our portfolio." The company also generated $1.77 billion in non-GAAP free cash flow during the quarter, helping lift its cash balance to $4.62 billion from $2.08 billion a year earlier. Looking into 2026, management initiated full-year adjusted diluted EPS guidance of $8.35 to $8.50, with core revenue expected to grow between 3% and 6%, led by roughly 6% core growth in Biotechnology, as the Life Sciences division is projected to be flat and Diagnostics expands at a low-single digit pace.

Key Takeaways

  • • Continued strength in bioprocessing business driving Biotechnology segment growth
  • • Improved momentum in Diagnostics and Life Sciences
  • • Disciplined execution exceeding margin, earnings, and cash flow expectations
  • • Cepheid respiratory revenue of approximately $500 million in Q4
24/7 Wall St

DHR YoY Financials

Q4 2025 vs Q4 2024, source: SEC Filings

24/7 Wall St

DHR Revenue by Segment

Business unit performance breakdown

“We delivered a strong finish to the year with better-than-expected performance across our portfolio. We were particularly encouraged by continued strength in our bioprocessing business, along with improved momentum in Diagnostics and Life Sciences. Our teams' disciplined execution also enabled us to exceed our fourth quarter margin, earnings, and cash flow expectations.”

— Rainer M. Blair, Q4 2025 Earnings Press Release

Back to DHR Stock Page